-
19/05/10 : Vaxon Biotech successfully completes its Phase I/II trial of Vx-001 cancer vaccine,Phase III ready to start in NSCLC
To download American / English version click here
-
20/02/09 : VAXON's lead product, Vx-001, has been granted orphan drug status by FDA for the treatment of NSCLC for HLA-A2+ patients with TERT+ tumours
-
08/10/08 : The Committee of Human Medicinal Products (CHMP) of the EMA officialy approved the development plan of the Vx-001 and particularly the design and objectives of the pivotal phase III clinical trial of the Vx-001 in NSCLC.
-
30/05/08 : VAXON Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the ASCO 2008 Annual Meeting
To download ASCO 2008 Abstract click here
-
11/04/08 : VAXON Biotech to Present Latest Clinical and Immunological Data of its Vx-001 Cancer Vaccine at the 99th AACR Annual Meeting
To download American / English version click here
-
16/11/07 : VAXON Biotech Receives from EMA an European Orphan Medicinal Product Designation for Vx-001
To download American / English version click here
Télécharger la version française en cliquant ici
-
02/07/07 : VAXON Biotech publishes encouraging results in the Journal of Clinical Oncology for the treatment of Non-Small Cell Lung Cancer with Vx-001.
To download American / English version click here
-
03/06/07 : VAXON Biotech Presents Preliminary Results from Vx-001 Vaccine Clinical Trial on Lung Cancer at the ASCO 2007 annual meeting
To download American / English version click here
-
03/04/06 : VAXON Biotech and Institut Pasteur Announce Collaboration to Develop New Products and Models for Cancer Immunotherapy
To download American / English version click here
-
14/03/06 : VAXON Biotech to Present Latest Clinical Data of its Vx-001 Cancer Vaccine at the 97th AACR Annual Meeting
To download American / English version click here
top of page
home .
contact .
terms of use .
sitemap .
Contact & directions